Bartlett, Nancy L <br/><br/>
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.  [electronic resource] 

 -  Journal of hematology & oncology  Mar 2014 
 - 24 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1756-8722 
<br/><br/><label>Standard No.: </label>10.1186/1756-8722-7-24  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Brentuximab Vedotin<br/>Female<br/>Hodgkin Disease--drug therapy<br/>Humans<br/>Immunoconjugates--administration & dosage<br/>Ki-1 Antigen--metabolism<br/>Lymphoma, Large-Cell, Anaplastic--drug therapy<br/>Male<br/>Middle Aged<br/>Molecular Targeted Therapy<br/>Recurrence<br/>Retreatment<br/>Young Adult